Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Brenner

Cardiovascular Disease Santa Rosa, CA Medical Doctor

NPI 1750561973 CMS profile 755158

34 Mark West Springs Rd Ste 310, Ste 300, Santa Rosa, CA 95403

Open in the dashboard

General payments

$15,600

296 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Brenner of Santa Rosa, CA is reported in the CMS Open Payments database as having received $15,600 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,765 71
2024 General $894 27
2023 General $1,339 33
2022 General $3,976 50
2021 General $1,005 30
2020 General $706 39
2019 General $1,915 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Brenner
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Daniel Brenner were reported at $5,765. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Daniel Brenner Cardiovascular Disease median Middle half National median
2019 $1,915 $450 $127–$1,392 $163
2020 $706 $242 $77–$751 $114
2021 $1,005 $335 $101–$1,037 $132
2022 $3,976 $395 $121–$1,211 $149
2023 $1,339 $443 $136–$1,283 $160
2024 $894 $450 $136–$1,323 $164
2025 $5,765 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $8,087 76 payments
  2. Abbott Laboratories $1,617 32 payments
  3. Boston Scientific Corporation $844 26 payments
  4. Abiomed $612 15 payments
  5. Philips Electronics North America Corporation $567 19 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $509 7 payments
  7. Medtronic Vascular, Inc. $456 11 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $370 33 payments
  9. Amgen Inc. $323 10 payments
  10. Inari Medical, Inc. $300 2 payments
  11. Other $1,915 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,454 267 payments
  2. Travel and Lodging $6,131 28 payments
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. SYMPLICITY G3 $2,192 21 payments
  2. FFRANGIO $722 7 payments
  3. Micra $615 11 payments
  4. Impella $440 13 payments
  5. JARDIANCE $414 7 payments
  6. CT THROMBECTOMY SYSTEM KIT $378 4 payments
  7. FLOWTRIEVER CATHETER, S $378 4 payments
  8. Mitra Clip system $377 2 payments
  9. LifeVest $370 33 payments
  10. Repatha $286 8 payments
  11. Other $5,859 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

7,164

Median for Interventional Cardiology: 2,236

Drug cost

$2,127,377

Median for Interventional Cardiology: $380,412

Branded share of claims

37.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 566 $656,846
Entresto Sacubitril/Valsartan Brand 617 $602,614
Farxiga Dapagliflozin Propanediol Brand 219 $236,196
Jardiance Empagliflozin Brand 158 $186,276
Repatha Sureclick Evolocumab Brand 108 $119,065
Xarelto Rivaroxaban Brand 102 $117,423
Nexlizet Bempedoic Acid/Ezetimibe Brand 49 $31,736
Brilinta Ticagrelor Brand 49 $30,798
Praluent Pen Alirocumab Brand 24 $28,743
Wegovy Semaglutide Brand 11 $19,335

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$334,509

Of which drugs: $319

Medicare patients

1,505

Average age 76

Services billed

5,057

717 women, 788 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Arthritis 43%
Atrial fibrillation 38%
Heart failure 37%
Chronic kidney disease 32%
Diabetes 31%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 19 76 $319

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record